bcd-089
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT03103438)
Timeline
Indications
Mechanism of action
- Interleukin-6 receptor alpha subunitINHIBITOR
Interleukin-6 receptor alpha subunit inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650406 ↗
Also known as
- bcd-089
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05800327 | Phase 3 | Dec 7, 2022 | Biocad |
| NCT04397562 | Phase 3 | Apr 29, 2020 | Biocad |
| NCT04227366 | Phase 3 | Nov 19, 2019 | Biocad |
| NCT03455842 | Phase 2 | Feb 1, 2018 | Biocad |
| NCT03103438 | Phase 1 | Nov 1, 2016 | Biocad |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocad | For profit | 5 | 5 | 3 | 2016 |
1 organizations
Page 1 / 1